Plus Therapeutics is developing targeted radiotherapeutics for CNS cancers, testing the product REYOBIQ in the ReSPECT-LM trial.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Plus Therapeutics is developing targeted radiotherapeutics for CNS cancers, testing the product REYOBIQ in the ReSPECT-LM trial.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Plus Therapeutics
biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswirePlus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome me